Researchers should note this distinction when transitioning between different peptide protocols
Here is a side-by-side comparison based on available trial data: Semaglutide 2.4 mg (Wegovy): 14.9% average weight loss over 68 weeks, GLP-1 receptor agonist only Tirzepatide 15 mg (Zepbound/Mounjaro): 20.9% average weight loss over 72 weeks, dual GLP-1 and GIP agonist Retatrutide 12 mg: 24.2% average weight loss over 48 weeks, triple GLP-1, GIP, and glucagon agonist What I found interesting in the data is that retatrutide appears to produce faster early weight loss than either semaglutide or tirzepatide
Glutathione exists in two distinct states within the body: the active, electron-rich form known as reduced glutathione (GSH), and the spent, inactive form known as oxidized glutathione (GSSG)
People commonly notice their energy picking up, their thinking feeling clearer, and that general heaviness starting to lift
Some practitioners suggest that glutathione injection during fasted states may enhance cellular uptake and utilization, as cells may be more receptive to antioxidant support when not processing dietary nutrients